Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Alaunos Therapeutics Inc
TCRT | US
3.65
USD0.04
1.11%
TCRT | US
Loading StockChartView...
About Alaunos Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
3.65
Open
3.65
High
3.65
Low
3.49
Alaunos Therapeutics Inc. a clinical-stage oncology-focused cell therapy company develops adoptive TCR engineered T-cell therapies. It develops TCR Library which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS TP53 and EGFR from its TCR library for the treatment of non-small cell lung colorectal endometrial pancreatic ovarian and bile duct cancers; hunTR a human neoantigen T-cell receptor engine. The company has a license agreement with PGEN Therapeutics Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology Inc. and changed its name to Alaunos Therapeutics Inc. in January 2022. Alaunos Therapeutics Inc. was founded in 2003 and is headquartered in Houston Texas.
View LessTCRT | US
Risk
44.6
Sharpe
1.09
Luna's Score
48/100
Recommendation
Hold
Luna says (TCRT | US)
What's Working
Positive Momentum
Value Stock (Price to Book < 3)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
45.8%1 month
44.6%3 months
83.7%6 months
96.2%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.94
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-3.55
Ent. to rev.
724.36
PEG
-
Other Fundamentals
EBITDA
-12.58M
MarketCap
5.84M
MarketCap(USD)
5.84M
Div. yield
-
Op. margin
-29.15K
Erngs. growth
-
Rev. growth
-
Ret. on equity
-150.50
Short ratio
4.84
Short perc.
9.48
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
1.04
Range1M
1.19
Range3M
2.16
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.72
Price X volume
37.81K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.55 | 0.53 | Cheaper |
| Ent. to Revenue | 724.36 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.94 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 83.66 | 72.80 | Par |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 5.84M | 3.66B | Emerging |
